New hope for asian brain tumor patients: targeted pill slows cancer growth

NCT ID NCT06780930

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests an experimental pill, vorasidenib, in Asian patients with a slow-growing but serious brain tumor (grade 2 glioma) that has a specific genetic mutation (IDH1 or IDH2). About 57 participants will receive either the drug or a placebo to see if it delays tumor progression. The goal is to offer a less toxic alternative to chemotherapy or radiation.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESIDUAL OR RECURRENT GRADE 2 IDH MUTANT GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytoma, IDH-mutant, grade 2

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chang Gung Memorial Hospital,

    Taoyuan, Taiwan

  • Huashan Hospital Fudan University

    Shanghai, 200040, China

  • Sanbo Brain Hospital, Capital Medical University

    Beijing, China

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • The Second Affiliated Hospital of Air Force Military Medical University

    Xi'an, China

  • The Second People's Hospital of Shenzhen

    Shenzhen, Guangdong, China

  • Tiantan Hospital

    Beijing, 100070, China

  • West China Hospital Sichuan University

    Chengdu, Sichuan, China